Hedegaard H, Spencer MR. Urban-rural differences in drug overdose death rates, 1999–2019. NCHS Data Brief. 2021;(403):1–8.
Rossen LM, Khan D, Warner M. Trends and geographic patterns in drug-poisoning death rates in the U.S., 1999–2009. Am J Prev Med. 2013;45(6):e19–25.
Callaghan T, Kassabian M, Johnson N, Shrestha A, Helduser J, Horel S, et al. Rural healthy people 2030: new decade, new challenges. Prev Med Rep. 2023;33:102176.
Baumgartner JC, Radley DC. Overdose deaths declined but remained near record levels during the first nine months of 2022 as states cope with synthetic opioids. Commonweath Fund 13, 2023.
Gong G, Phillips SG, Hudson C, Curti D, Philips BU. Higher US rural mortality rates linked to socioeconomic status, physician shortages, and lack of health insurance. Health Aff (Millwood). 2019;38(12):2003–10.
Carroll C, Euhus R, Beaulieu N, Chernew ME. Hospital survival in rural markets: closures, mergers, and profitability. Health Aff (Millwood). 2023;42(4):498–507.
Center for Healthcare Quality and Payment Reform. Retrieved from https://ruralhospitals.chqpr.org/downloads/Rural_Hospitals_at_Risk_of_Closing.pdf.
Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Public Health. 2015;129(6):611–20.
McCarty D, Donovan DM. The National Drug Abuse Treatment Clinical Trials Network: from 2000 to 2020 and beyond. J Subst Abuse Treat. 2020;112S:1–3.
Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, et al. Rural Opioid Initiative. The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. Addict Sci Clin Pract. 2022;17(1):38.
Walters SM, Bolinski RS, Almirol E, Grundy S, Fletcher S, Schneider J, et al. Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis. Addict Sci Clin Pract. 2022;17(1):24.
Singh GK, Daus GP, Allender M, Ramey CT, Martin EK, Perry C, et al. Social determinants of health in the United States: addressing major health inequality trends for the nation, 1935–2016. Int J MCH AIDS. 2017;6(2):139–64.
Burton MJ, Voluse AC, Patiel AB. Supporting direct acting antiviral medication adherence and treatment completion in a sample of predominantly rural veterans with hepatitis c and substance use disorders. Addict Sci Clin Pract. 2024 June;25:19:51.
Pasman E, Kollin R, Broman M, Lee G, Agius E, Lister JJ, et al. Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. Addict Sci Clin Pract. 2022;17(1):35.
Smith CL, Rodin NM, Hwang JY, Miguel AQC, Johnson K, McDonell MG, et al. Automated reinforcement management system (ARMS): focused phase I provider feedback. Addict Sci Clin Pract. 2022;17(1):20.
McNeely J, McLeman B, Gardner T, Nesin N, Amarendran V, Farkas S, et al. Implementation of substance use screening in rural federally-qualified health center clinics identified high rates of unhealthy alcohol and cannabis use among adult primary care patients. Addict Sci Clin Pract. 2023;18(1):56.
Levander XA, Wheelock H, Pope J, Lee A, Hartmann K, Abuelkhair S et al. Low-threshold buprenorphine via community partnerships and telemedicine-case reports of expanding access to addiction treatment during COVID-19. J Addict Med 2022 Jan-Feb 01;16(1):e56–8.
Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S, Greenblatt A, Welsh C, Pappas A, Ross TL, Belcher AM. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open. 2021;4(8):e2118487.
Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J. Low-barrier buprenorphine during the COVID-19 pandemic: a rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat. 2021;131:108444.
Hser YI, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, et al. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a national drug abuse treatment clinical trials Network Trial. Addict Sci Clin Pract. 2021;16(1):24.
Schoenberg N, Dunfee M, Yeager H, Rutledge M, Pfammatter A, Spring B. Rural residents’ perspectives on an mHealth or personalized health coaching intervention: qualitative study with focus groups and key informant interviews. JMIR Form Res. 2021;5(2):e18853.
Brockman TA, Shaw O, Wiepert L, Nguyen QA, Kelpin SS, West I, et al. Community engagement strategies to promote recruitment and participation in clinical research among rural communities: a narrative review. J Clin Transl Sci. 2023;7(1):e84.
Winstanley EL, Stroup-Menge B, Snyder K. The promise of technology-based services for addiction treatment clients residing in nonurban areas. J Stud Alcohol Drugs. 2018;79(3):503–4.
Winstanley EL, Lander LR, Zheng W, Law KB, Six-Workman A, Berry JH. Rapid transition of individual and group-based behavioral outpatient visits to telepsychiatry in response to COVID-19. J Addict Med 2021 May-Jun 01;15(3):263–5.
Haggerty T, Turiano NA, Turner T, Dekeseredy P, Sedney CL. Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care. Addict Sci Clin Pract. 2022;17(1):72.
Murray OB, Doyle M, McLeman BM, Marsch LA, Saunders EC, Cox KM, et al. Augmenting project ECHO for opioid use disorder with data-informed quality improvement. Addict Sci Clin Pract. 2023;18(1):24.
Stone EM, Kennedy-Hendricks A, Barry CL, Bachhuber MA, McGinty EE. The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug Alcohol Depend. 2021;221:108627.
Solmeyer AR, Berger AT, Barton SL, Nguyen B, Bart GB, Grahan B, et al. Association of project ECHO training with buprenorphine prescribing by primary care clinicians in Minnesota for treating opioid use disorder. JAMA Health Forum. 2022;3(11):e224149.
Anderson JB, Martin SA, Gadomski A, Krupa N, Mullin D, Cahill A, Jenkins P. Project ECHO and primary care buprenorphine treatment for opioid use disorder: implementation and clinical outcomes. Subst Abus. 2022;43(1):222–30.
Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):72.
Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722–9.
Johnson Q, Mund B, Joudrey PJ. Improving rural access to opioid treatment programs. J Law Med Ethics. 2018;46(2):437–9.
Nguyen BD, Li L, Chunqing L, et al. Confidence in providing methadone maintenance treatment of primary care 2 providers in Vietnam. Addict Sci Clin Pract. 2024;19:43.
Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas – United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(48):1337–41.
Grebely J, Dore GJ. Prevention of Hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis. 2011;203(5):571–4.
Romo E, Rudolph AE, Stopka TJ, Wang B, Jesdale BM, Friedmann PD. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England. Addict Sci Clin Pract. 2023;18(1):2.
Gupta A, Shebl FM, Tong Y, Wagner K, Bassett IV, Page K, et al. Association of co-occurring mental health problems with hepatitis C status among young people who inject drugs in rural New Mexico, 2016–2018. Addict Sci Clin Pract. 2022;17(1):58.
Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006;163(11):1993–9.
DeFulio A. Dissemination of contingency management for the treatment of opioid use disorder. Perspect Behav Sci. 2022;46(1):35–49.
Knopf A. California is first state to establish Medicaid waiver for CM. Alcoholism Drug Abuse Wkly. 2022;34:1–4.
Watson DP, Staton MD, Gastala N. Identifying unique barriers to implementing rural emergency department-based peer services for opioid use disorder through qualitative comparison with urban sites. Addict Sci Clin Pract. 2022;17(1):41.
Rogers EM. Diffusion of preventive innovations. Addict Behav. 2002;27:989–93.
Ozbay F, Johnson DC, Dimoulas E, Morgan CA, Charney D, Southwick S. Social support and resilience to stress: from neurobiology to clinical practice. Psychiatry (Edgmont). 2007;4(5):35–40.
Gliedt JA, Spector AL, Schneider MJ, Williams J, Young S. A description of theoretical models for health service utilization: a scoping review of the literature. Inquiry. 2023 Jan-Dec;60:469580231176855.
Stack E, Hildebran C, Leichtling G, Waddell EN, Leahy JM, Martin E et al. Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings – a narrative review. J Addict Med 2022 Jan-Feb 01;16(1):93–100.
Herink MC, Seaman A, Leichtling G, Larsen JE, Gailey T, Cook R, et al. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the peer tele-HCV study. Addict Sci Clin Pract. 2023;18(1):35.
Strasser R. Rural health around the world: challenges and solutions. Fam Pract. 2003;20(4):457–63.
Add Comment